Metabolomic differences between exanthematous drug eruption and infectious mononucleosis
Skin Research and Technology · 2024
DOI: 10.1111/srt.70043 ↗At a glance
Journal article in Skin Research and Technology, 2024. Written by Yanqiu Liu and 5 co-authors. Institution: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China. Major MEDLINE topics: Drug Eruptions, Metabolomics, Infectious Mononucleosis, Biomarkers. Cited 1 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Hebei Provincial Department of Science and Technology.
Abstract (original language)
Background
Exanthematous drug eruption and infectious mononucleosis (IM) are both exanthematous diseases. Current research on exanthematous drug eruption and IM mainly targets identifying these disorders, the resulting differences at the metabolism level have not yet been systematically analyzed. Materials and methods A total of 30 cases of exanthematous drug eruption and IM, 10 patients without exanthema and 10 healthy volunteers were enrolled, 3 mL of fasting venous blood was collected, the serum metabolite content was detected by gas chromatography‐mass spectrometry metabolomics.
Results
A total of 165 metabolites were identified, exhibiting significant differences in plasma metabolic trends between exanthematous drug eruption and IM, and pinpointed 28 potential biomarkers. Notable changes were seen in the metabolic activities of the pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA‐cycle), and galactose metabolism, characterized by increased levels of gluconate, gluconolactone, glucose, galactaric acid, and mannose, along with decreased amounts of pyruvic acid, succinic acid, malic acid, and glycerol, indicating an impairment in the exanthematous drug eruption group's capacity to endure oxidative stress and regulate energy metabolism. In contrast to its medication without rash counterpart, the exanthematous drug eruption group's plasma displayed distinct metabolic routes, predominantly in the processing of arginine and proline, along with the TCA. This resulted in a marked reduction in urea levels and a rise in pyruvate, citrate, and ornithine, indicating hypoxic stress as the primary cause of these rashes. In contrast to the healthy control group, the IM group showed 26 potential biomarkers, marked by increased levels of ketoglutaric acid, malic acid, pyruvic acid, and oxoglutaric acid, and reduced amounts of glutamine, galacturonic acid, arachidonic acid, trimethylphosphonic acid ester, gluconolactone, and indole acetic acid. Mainly, the metabolic pathways included the TCA, breaking down alanine, aspartate and glutamate metabolism, and the processing of D‐glutamine and D‐glutamate metabolism, underscoring the body's crucial role in generating energy and inflammatory agents through the citric acid cycle.
Conclusions
The comparison of serum metabolomic features of exanthematous drug eruptions and IM outlines a unique pattern closely related to the differences in the pathogenesis of these two exanthematous diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
- Clinical lab, Chengde central Hospital, Chengde, China.
ORCID profiles: Yanqiu Liu
Funding
- Hebei Provincial Department of Science and Technology
Cite
APA
Liu, Y., Guan, Q., Liu, L., Ma, L., Duan, X., & Che, J. (2024). Metabolomic differences between exanthematous drug eruption and infectious mononucleosis. Skin Research and Technology. https://doi.org/10.1111/srt.70043
Vancouver
Liu Y, Guan Q, Liu L, Ma L, Duan X, Che J. Metabolomic differences between exanthematous drug eruption and infectious mononucleosis. Skin Research and Technology. 2024. doi:10.1111/srt.70043
BibTeX
@article{Liu2024,
author = {Liu, Yanqiu and Guan, Qizhen and Liu, Liyuan and Ma, Lina and Duan, Xinsuo and Che, Jiaozi},
title = {Metabolomic differences between exanthematous drug eruption and infectious mononucleosis},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.70043}
}
EUVIMED